Two years of empagliflozin treatment in patients with chronic kidney disease slowed progression and reduced cardiovascular risk. Findings from a 2-year post-trial follow-up are summarized in a ...

Jardiance is also authorised to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. According to the FDA, heart disease impacts more than ...

Farxiga (dapagliflozin) and Jardiance (empagliflozin) are prescription medications that are commonly used for type 2 diabetes ...

Earlier this week, German manufacturer Boehringer Ingelheim’s patent to manufacture Empagliflozin, a medication to treat type 2 diabetes mellitus, expired in India. Empagliflozin is sold under ...

Mankind Pharma has launched its affordable generic version empagliflozin in India for diabetes following its patent expiration. The launch follows patent expiration of empagliflozin sold by German ...

Corona Remedies Limited has launched its generic version of empagliflozin introduced under the brand name “Empabite & combinations”, a SGLT-2 inhibitor for type 2 diabetes. With a commitment to ...

Glenmark Pharmaceuticals announced today the launch of Empagliflozin and its fixed-drug combinations in India under the brand names Glempa, Glempa-L, and Glempa-M. The shares of Glenmark ...

Mumbai-based Alkem Laboratories announced today the launch of generic empagliflozin and its combinations in India under the brand name “Empanorm.” The medication, which treats type-2 diabetes ...